Chinese pharmaceutical companies Sanyou Biopharmaceutical Co Ltd and Guangzhou Baiyunshan Xihe Health Pharmaceutical Co Ltd announced on Saturday that they have entered into a strategic cooperation agreement.

The partnership will focus on the co-development of novel radiopharmaceuticals and radiodiagnostic products, aiming to integrate their respective core strengths in AI-driven innovative drug molecule discovery and the full industrial value chain of nuclear medicine. Together, the two parties seek to build an end-to-end innovation chain spanning from target molecule discovery to clinical translation of radiopharmaceuticals, delivering more transformative solutions for precision oncology diagnosis and therapy.

Sanyou Bio will leverage its AI-Super trillion antibody/molecule libraries (AI-STAL) and its Sanyou AI-Drug Accelerator (SAI-DA) to provide source innovation power for the discovery and optimisation of high-performance antibodies and targeting molecules against specific targets. Baiyunshan Xihe will rely on its end-to-end capabilities in novel medical radionuclide production, GMP manufacturing, and clinical translation to advance partnered molecules into radiolabelling, in vitro and in vivo evaluation, and preclinical studies, accelerating the industrialisation of innovative radiopharmaceuticals and radiodiagnostic products.